Входя на эту страницу, Вы подтверждаете, что являетесь  медицинским работником.

Status message

Not the entire site translated, but only to "Magazine"

INFLUENCE OF SINGLE NUCLEOTIDE VARIANTOF GENE LEP (rs3828942) ON ANTIPSYCHOTIC-INDUCED ABNORMAL GLUCOSE METABOLISMIN PATIENTS WITH SCHIZOPHRENIA

V.S. Dobrodeeva 1, M.Y. Tolmachev 1, N.A. Shnayder 1, Neznanov N.G. 1 , R.F. Nasyrova 1, 2, 3
1
V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology, St. Petersburg, Russia
2 P.P. Kashchenko Psychiatric Hospital No 1, St. Petersburg, Russia
3 Kazan Federal University, Respublica Tatarstan, Kazan, Russia
Purpose: To study the influence of the polymorphic variant of the LEP gene Lys656Asn (rs3828942) on antipsychotic-induced changes in glucose concentration in patients residing in the European part of Russian Federation.
Materials and methods: A prospective study included 117 adult patients based on the presence of F2 disorders according to ICD-10 and the absence of serious somatic disorders residing in the European part of Russian Federation. Patients took antipsychotics in monotherapy.
Results: A allele of Lys656Asn polymorphism (rs3828942) of the LEP gene is associated with glucose concentration more than 6.1 mmol/L during antipsychotic therapy
Conclusions: Genetic polymorphisms of the leptin system (LEP Lys656Asn) could be a predictor of pre-diabetic state development during antipsychotic therapy.
Contact: nreginaf77@gmail.com
Citation:
V.S. Dobrodeeva, M.Y. Tolmachev, N.A. Shnayder, R.f. Nasyrova. Influence of single nucleotide variantof gene LEP (rs3828942) on antipsychotic-induced abnormal glucose metabolismin patients with schizophrenia // Sovrem. ter. psih. rasstrojstv. – 2020. – Vol. 1. – P. 16-20. DOI: 10.21265/PSYPH.2020.37.30.002

References:

1. Phan S.V., Kreys T.-J.M. Adjunct Mirtazapine for negative symptoms of schizophrenia // Pharmacotherapy [Internet]. – Wiley. – 2011, Oct. – Vol. 31 (10). P. 1017–1030. – Available from: http://dx.doi.org/10.1592/phco.31.10.1017
2. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis // The Lancet [Internet]. – Elsevier BV. – 2009, Jan. – Vol. 373 (9657). –P. 31–41. – Available from: http://dx.doi.org/10.1016/s0140-6736(08)61764-x
3. Meltzer H.Y. The Role of serotonin in antipsychotic drug action // Neuropsychopharmacology [Internet]. – Springer Nature. – 1999, Aug. – Vol. 21. – S. 106–115. – Available from: http://dx.doi.org/10.1038/sj.npp.1395370
4. Foussias G., Remington G. Antipsychotics and schizophrenia: From efficacy and effectiveness to clinical decision-making // The Canadian Journal of Psychiatry [Internet]. – SAGE Publications. – 2010, Mar. – Vol. 55 (3). – P. 117–125. – Available from: http://dx.doi.org/10.1177/070674371005500302
5. Malhotra A.K., Zhang J.-P., Lencz T. Pharmacogenetics in psychiatry: translating research into clinical practice // Molecular Psychiatry [Internet]. – Springer Nature. – 2011, Nov. 15. – Vol. 17 (8). – P. 760–769. – Available from: http://dx.doi.org/10.1038/mp.2011.146
6. Müller D. Pharmacogenetics of antipsychotic-induced weight gain // Pharmacological Research [Internet]. – Elsevier BV. – 2004, Apr, – Vol. 49 (4). – P. 309–329. – Available from: http://dx.doi.org/10.1016/j.phrs.2003.05.001
7. Kyrou I., Randeva H.S., Tsigos C., Kaltsas G., Weickert M.O. Clinical problems caused by obesity [Internet]. – Last Update: January 11, 2018. – Available from: https://www.ncbi.nlm.nih.gov/books/NBK278973/
8. Meyer J.M. Novel antipsychotics and severe hyperlipidemia // Journal of Clinical Psychopharmacology [Internet]. – Ovid Technologies (Wolters Kluwer Health). – 2001, Aug. – Vol. 21 (4). – P. 369–374. – Available from: http://dx.doi.org/10.1097/00004714-200108000-00003
9. The IDF consensus worldwide definition of the metabolic syndrome // Obesity and metabolism [Internet]. – Endocrinology Research Centre. – 2005, Sep. – Vol. 15 (3). – P. 47. – Available from: http://dx.doi.org/10.14341/2071-8713-4854
10. Allison D.B., Mentore J.L., Heo M. et al. Antipsychotic-induced weight gain: a comprehensive research synthesis // Am. J Psychiatry. – 1999. –Vol. 156 (11). – P. 1686–1696.
11. Gregoor J.G., van der Weide J., Loovers H.M., van Megen H.J., Egberts T.C., Heerdink E.R. Polymorphisms of the LEP, LEP and HTR2C gene: obesity and BMI change in patients using antipsychotic medication in a naturalistic setting // Pharmacogenomics [Internet]. – Future Medicine Ltd. – 2011, Jun. – Vol. 12 (6). – P. 919–923. – Available from: http://dx.doi.org/10.2217/pgs.11.40
12. Ruaño G., Goethe J.W., Caley C., Woolley S., Holford T.R., Kocherla M. et al. Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients // Molecular Psychiatry [Internet]. – Springer Nature. – 2007, Jan 2. – Vol. 12 (5). P. 474–482. – Available from: http://dx.doi.org/10.1038/sj.mp.4001944
13. Ringen P.A., Engh J.A., Birkenaes A.B., Dieset I., Andreassen O.A. Increased mortality in schizophrenia due to cardiovascular disease: A non-systematic review of epidemiology, possible causes, and interventions // Frontiers in Psychiatry [Internet]. – Frontiers Media SA. – 2014, Sep. – Vol. 26. – P. 5. – Available from: http://dx.doi.org/10.3389/fpsyt.2014.00137
14. Minet-Ringuet J., Even P.C., Valet P., Carpéné C., Visentin V., Prévot D. et al. Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment // Molecular Psychiatry [Internet]. – Springer Nature. – 2007, Jan. 9. – Vol. 12 (6). – P. 562–571. – Available from: http://dx.doi.org/10.1038/sj.mp.4001948
15. Varela L., Horvath T.L. Leptin and insulin pathways in POMC and AgRP neurons that modulate energy balance and glucose homeostasis // EMBO reports [Internet]. – Wiley. – 2012, Nov. 13. – Vol. 13 (12). – P. 1079–1086. – Available from: http://dx.doi.org/10.1038/embor.2012.174
16. Vaisse C., Halaas J.L., Horvath C.M., Darnell J.E., Stoffel M., Friedman J.M. Leptin activation of Stat3 in the hypothalamus of wild–type and ob/ob mice but not db/db mice // Nature Genetics [Internet]. – Springer Nature. – 1996, Sep. – Vol. 14 (1). – P. 95–97. Available from: http://dx.doi.org/10.1038/ng0996-95
17. Mesaros A., Koralov S.B., Rother E., Wunderlich F.T., Ernst M.B., Barsh G.S. et al. Activation of Stat3 signaling in AgRP neurons promotes locomotor activity // Cell Metabolism [Internet]. – Elsevier BV. – 2008, Mar. –Vol. 7 (3). –P. 236–248. – Available from: http://dx.doi.org/10.1016/j.cmet.2008.01.007 
18. Van den Top M., Lee K., Whyment A.D., Blanks A.M., Spanswick D. Orexigen-sensitive NPY/AgRP pacemaker neurons in the hypothalamic arcuate nucleus // Nature Neuroscience [Internet]. – Springer Nature. – 2004, Apr. 18. – Vol. 7 (5). – P. 493–494. – Available from: http://dx.doi.org/10.1038/nn1226